Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 10
Submit an article Journal homepage
1,461
Views
2
CrossRef citations to date
0
Altmetric
Hematology

Healthcare costs and resource utilization in patients with severe aplastic anemia in the US

Beilei CaiUS Oncology Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Correspondence[email protected]
,
Qayyim SaidUS Oncology Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;
,
Xin LiKMK Consulting Inc, Morristown, NJ, USA
,
Frank (Yunfeng) LiUS Oncology Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;
&
Steve ArconaUS Oncology Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;
Pages 1055-1062 | Received 28 May 2019, Accepted 10 Jul 2019, Published online: 04 Aug 2019

References

  • National Heart, Lung, and Blood Institute (NHLBI). What is aplastic anemia. 2018 [cited 2018 Aug 31]. Available from: https://www.nhlbi.nih.gov/node/80148.
  • Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–2519.
  • Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504–514.
  • Rosenfeld S, Follmann D, Nunez O, et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130–1135.
  • Dunkirk SG, Gregg SL, Duran LW, et al. Photochemical coatings for the prevention of bacterial colonization. J Biomater Appl. 1991;6:131–156.
  • de Latour RP, Huynh L, Ivanova JI, et al. A retrospective chart review to assess burden of illness among patients with severe aplastic anemia with insufficient response to immunosuppressive therapy. Blood. 2017;130:678
  • Joshi S, Rose MJ, Stanek JR, et al. A comparison of resource utilization, cost and mortality in children treated for severe aplastic anemia. Blood. 2016;128.2333.
  • Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123:1818–1825.
  • Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–19.
  • Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540–1550.
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
  • Lee CH, Lee JH, Kim HM. Flexible integration of laser myringotomy and ventilation tube for bilateral Otitis media with effusion: analysis of laser tympanostomy versus ventilation tube. PLoS One. 2014;9:e84966.
  • DeZern AE, Guinan EC. Aplastic anemia in adolescents and young adults. Acta Haematol. 2014;132:331–339.
  • Dieguez G, Ferro C, Rotter D. Milliman Research Report. The cost burden of blood cancer care. Commissioned by the Leukemia & Lymphoma Society; 2018.
  • Tremblay G, Said Q, Cai B, et al. Comparing costs and consequences of Eltrombopag plus IST versus IST alone for first-line treatment in severe aplastic anemia: results from a responder analysis. Blood. 2018;132:1041.
  • Broder MS, Cai B, Chang E, et al. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database. BMC Pulm Med. 2018;18:135.
  • Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99:1574–1581.
  • Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187–207.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.